delavirdine and HIV
delavirdine has been researched along with HIV in 11 studies
Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
Research Excerpts
| Excerpt | Relevance | Reference |
|---|---|---|
| "Saquinavir was common in all study arms, and the study investigated relationships among characteristics of patients, saquinavir area under the curve (AUC) and trough concentrations (C(min)), and virologic response." | 2.71 | Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. ( Acosta, EP; Brundage, RC; Fletcher, CV; Gulick, RM; Haubrich, R; Jiang, H; Katzenstein, D, 2004) |
Research
Studies (11)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (27.27) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Wang, Z | 1 |
| Vince, R | 1 |
| Tian, Y | 1 |
| Du, D | 1 |
| Rai, D | 1 |
| Wang, L | 1 |
| Liu, H | 1 |
| Zhan, P | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Liu, X | 1 |
| Gu, SX | 1 |
| Xue, P | 1 |
| Ju, XL | 1 |
| Zhu, YY | 1 |
| Kuo, YC | 1 |
| Lee, CL | 1 |
| Gulick, RM | 2 |
| Hu, XJ | 1 |
| Fiscus, SA | 1 |
| Fletcher, CV | 2 |
| Haubrich, R | 2 |
| Cheng, H | 1 |
| Acosta, E | 1 |
| Lagakos, SW | 1 |
| Swanstrom, R | 1 |
| Freimuth, W | 1 |
| Snyder, S | 1 |
| Mills, C | 1 |
| Fischl, M | 1 |
| Pettinelli, C | 1 |
| Katzenstein, D | 2 |
| Jiang, H | 1 |
| Brundage, RC | 1 |
| Acosta, EP | 1 |
| Gianotti, N | 1 |
| Boeri, E | 1 |
| Maillard, M | 1 |
| Serra, G | 1 |
| Ratti, D | 1 |
| Gallotta, G | 1 |
| Vacchini, D | 1 |
| Tremolada, Y | 1 |
| Castagna, A | 1 |
| Miller, V | 1 |
| Staszewski, S | 1 |
| Boucher, CA | 1 |
| Phair, JP | 1 |
| James, JS | 1 |
| Bowers, M | 1 |
Clinical Trials (2)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Activity of the Soft Gelatin Capsule of Saquinavir (SQVsgc) in Combination With Ritonavir or Nelfinavir and Combinations of Delavirdine and/or Adefovir Dipivoxil in HIV-Infected Subjects With Prior Indinavir Use and Viral Loads From 2,000 to 200,000 Copie[NCT00000892] | 300 participants | Interventional | Completed | ||||
| CID 0708 - Sex, Aging and Antiretroviral Pharmacokinetics[NCT00666055] | 11 participants (Actual) | Observational | 2008-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reviews
2 reviews available for delavirdine and HIV
| Article | Year |
|---|---|
Advances in rationally designed dual inhibitors of HIV-1 reverse transcriptase and integrase.
Topics: Anti-HIV Agents; Drug Design; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Reverse Transcripta | 2016 |
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Animals; Anti-HIV Agents; Delavirdine; HIV; HIV Infections; Nevirapine; N | 1997 |
Trials
2 trials available for delavirdine and HIV
| Article | Year |
|---|---|
Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Delavirdine; Double-Blind Method; Drug Therapy, Combination; | 2002 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359.
Topics: Adenine; Adult; Anti-HIV Agents; Delavirdine; Double-Blind Method; Drug Therapy, Combination; Female | 2004 |
Other Studies
7 other studies available for delavirdine and HIV
| Article | Year |
|---|---|
Design and synthesis of dual inhibitors of HIV reverse transcriptase and integrase: introducing a diketoacid functionality into delavirdine.
Topics: Delavirdine; Drug Design; HIV; HIV Integrase; HIV Integrase Inhibitors; HIV Reverse Transcriptase; K | 2008 |
Fused heterocyclic compounds bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 1: design, synthesis and biological evaluation of novel 5,7-disubstituted pyrazolo[1,5-a]pyrimidine derivatives.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Design; Heterocyclic Compounds; HIV; HIV Rev | 2014 |
Methylmethacrylate-sulfopropylmethacrylate nanoparticles with surface RMP-7 for targeting delivery of antiretroviral drugs across the blood-brain barrier.
Topics: Ammonium Sulfate; Anti-HIV Agents; Astrocytes; Biological Transport; Blood-Brain Barrier; Bradykinin | 2012 |
In vivo dynamics of the 103N mutation following the withdrawal of non-nucleoside reverse transcriptase inhibitors in HIV-infected patients: preliminary results.
Topics: Alkynes; Amino Acid Substitution; Base Sequence; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; | 2004 |
Viral load: new confirmation from major delavirdine studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Delavirdine; HIV; HIV Infections; | 1996 |
Non-nucleoside reverse transcriptase inhibitors.
Topics: Acetamides; Acetophenones; Antiviral Agents; Delavirdine; Drug Approval; Drug Resistance, Microbial; | 1996 |
Delavirdine (Rescriptor).
Topics: Delavirdine; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Practice Guidelines as Topic; | 2000 |